Q-omics provides the consensus-scored UBXN2B profile across patient tissues and cancer cell-line models. UBXN2B expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, UBXN2B is differentially expressed in 10, with the highest sampling consensus in LIHC. Additionally, UBXN2B RNA expression shows 20,249 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, LIHC, and UVM as cancer lineages where UBXN2B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for UBXN2B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes UBXN2B survival associations across molecular data types. UBXN2B RNA expression shows survival associations in the most cancer types (23), followed by mutation status (3) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible UBXN2B RNA expression–survival associations across cancer types. High UBXN2B expression shows unfavorable associations in UVM, UCEC and CESC, but favorable associations in KIRC, SKCM and UCS. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for UBXN2B RNA expression.
This table summarizes UBXN2B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 3. The strongest signals are observed in THCA for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for UBXN2B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. UBXN2B shows lower tumor expression in THCA and higher tumor expression in LIHC, HNSC, BRCA, STAD and LUAD. The LIHC box plot shows higher UBXN2B RNA expression in tumor versus normal tissue (log2 FC = +1.278, t-test p < 0.001).
This table shows molecular features associated with UBXN2B in patient tissues and cancer cell lines. In patient samples, UBXN2B shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, UBXN2B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BREAST.
